Verena Schönau, MD (she/her/hers)

Universitätsklinikum Erlangen
91054 Erlangen, Germany

MD

Presentation(s):

• 0762: Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); chugai: Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Roche: Grant/Research Support (Terminated, October 31, 2023)